Melane Sampson, Author at BioTuesdays

Developments

MAIA enters into agreement with Roche to investigate THIO with Tecentriq

MAIA Biotechnology (NYSE American: MAIA) announced it has entered into a master supply agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to investigate the combination of MAIA’s telomere-targeting agent ateganosine...

June 18, 2025

Developments

USPTO issues patent for Lipella’s diagnostic technology

Lipella Pharmaceuticals (NASDAQ: LIPO) announced that on June 10, 2025 the U.S. Patent and Trademark Office (USPTO) issued Patent No. 12,326,492, titled Systems and Methods of Detecting Interstitial Cystitis, providing...

June 17, 2025

Feature

Launchit Solutions enhancing patient outcomes through strategic partnerships and advanced medical programs

Launchit Solutions is leveraging breakthrough technology and clinically validated innovations to bring effective healthcare solutions to patients, with a focus on obesity management, support programs, life science...

June 17, 2025

Developments

Cellectar reports updates on Phase 1 study of iopoffosine I 131 in pHGG

Cellectar Biosciences (NASDAQ: CLRB) announced initial results as of June 10, 2025, from its CLOVER-2 Phase 1 trial evaluating iopoffosine I 131 in relapsed/refractory pediatric high-grade glioma (pHGG) patients...

June 11, 2025

Developments

Adial’s lead AUD candidate advances toward Phase 3 trial

Adial Pharmaceuticals (NASDAQ: ADIL) announced that its lead investigational candidate—AD04—a therapeutic agent for alcohol use disorder (AUD) is progressing toward a Phase 3 trial. According to Adial, as part of its...

June 11, 2025

Executive Moves

Beacon appoints Dr. Daniel Chung as CMO

Closely held Beacon Therapeutics announced the appointment of Dr. Daniel Chung as chief medical officer (CMO), effective immediately. Dr. Chung brings more than three decades of experience in ophthalmology, academic...

June 11, 2025

Executive Moves

Laura Conquergood joins Baylis as CEO

Closely held Baylis Medical Technologies announced the appointment of Laura Conquergood as chief executive officer (CEO). Kris Shah, formerly president and CEO, and Frank Baylis, formerly executive chairman, have both...

June 11, 2025

Feature

Arrivo developing novel medicines to target hard-to-treat diseases at their source

Closely held Arrivo BioVentures is developing novel, first-in-class medicines that target the underlying causes of diseases with high unmet need, aiming to achieve meaningful patient outcomes that extend and improve the...

June 10, 2025

Developments

Citius and Cardinal sign distribution agreement

Citius Oncology (NASDAQ: CTOR) announced it has entered into a distribution services agreement with Cardinal Health (NYSE: CAH). According to Citius, the agreement is designed to help provide access to LYMPHIR, an...

June 9, 2025

Developments

Leef acquires New York License

Leef Brands (CSE: LEEF; OTCQB: LEEEF) announced it has officially closed on the acquisition of a Type 1 Cannabis Processor License in New York, enabling the company to engage in extraction, blending, infusion...

June 9, 2025

Author - Melane Sampson

MAIA enters into agreement with Roche to investigate THIO with Tecentriq

USPTO issues patent for Lipella’s diagnostic technology

Launchit Solutions enhancing patient outcomes through strategic partnerships and advanced medical programs

Cellectar reports updates on Phase 1 study of iopoffosine I 131 in pHGG

Adial’s lead AUD candidate advances toward Phase 3 trial

Beacon appoints Dr. Daniel Chung as CMO

Laura Conquergood joins Baylis as CEO

Arrivo developing novel medicines to target hard-to-treat diseases at their source

Citius and Cardinal sign distribution agreement

Leef acquires New York License

Subscribe